Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A tick-triggered meat allergy just got a potential new management tool. A retrospective study of 64 high-risk alpha-gal syndrome patients found that none required epinephrine during omalizumab treatment, and 95% reported meaningful improvement in reaction frequency or severity. Researchers caution that avoidance remains the cornerstone of care, but anti-IgE therapy may offer a meaningful safety net.
Alpha-gal syndrome — a red meat allergy triggered by lone star tick bites — can make everyday eating a life-threatening gamble. New data suggest that omalizumab (Xolair) may help reduce that risk. Presented at the ACAAI Annual Scientific Meeting and awarded first place for the Clemens von Pirquet Abstract Award, the retrospective study followed 64 high-risk patients over a median of 23 months of omalizumab treatment.
The results were notable: not a single patient needed epinephrine for an alpha-gal reaction during treatment, despite 81% having documented anaphylaxis and 53% requiring epinephrine before starting the drug. Researchers were careful to note that omalizumab doesn't cure the condition or replace avoidance strategies — but it may meaningfully reduce the severity and frequency of reactions for those who remain at risk despite their best efforts.
Key Takeaways:
Why it matters: For patients living with the constant anxiety of accidental alpha-gal exposures — from hidden ingredients in processed foods to medications — omalizumab could offer a meaningful quality-of-life improvement. Prospective studies with larger, more diverse populations are still needed to confirm these findings.